BRPI9713914B8 - - Google Patents

Info

Publication number
BRPI9713914B8
BRPI9713914B8 BR9713914A BR9713914A BRPI9713914B8 BR PI9713914 B8 BRPI9713914 B8 BR PI9713914B8 BR 9713914 A BR9713914 A BR 9713914A BR 9713914 A BR9713914 A BR 9713914A BR PI9713914 B8 BRPI9713914 B8 BR PI9713914B8
Authority
BR
Brazil
Application number
BR9713914A
Other languages
Portuguese (pt)
Other versions
BR9713914A (pt
BRPI9713914B1 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25071323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9713914(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR9713914A publication Critical patent/BR9713914A/pt
Publication of BRPI9713914B1 publication Critical patent/BRPI9713914B1/pt
Publication of BRPI9713914B8 publication Critical patent/BRPI9713914B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI9713914-9A 1996-12-11 1997-12-09 Composition, use of the same, and, pharmaceutical composition BRPI9713914B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/764,640 US5869451A (en) 1995-06-07 1996-12-11 Peptides and compounds that bind to a receptor
US08/764640 1996-12-11
PCT/EP1997/006850 WO1998025965A2 (en) 1996-12-11 1997-12-09 Peptides and compounds that bind to the thrombopoietin receptor

Publications (3)

Publication Number Publication Date
BR9713914A BR9713914A (pt) 2000-02-29
BRPI9713914B1 BRPI9713914B1 (pt) 2017-06-20
BRPI9713914B8 true BRPI9713914B8 (OSRAM) 2021-05-25

Family

ID=25071323

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9713914-9A BRPI9713914B1 (pt) 1996-12-11 1997-12-09 Composition, use of the same, and, pharmaceutical composition

Country Status (24)

Country Link
US (2) US5869451A (OSRAM)
EP (3) EP0948539B1 (OSRAM)
JP (1) JP4128225B2 (OSRAM)
KR (3) KR100625708B1 (OSRAM)
CN (1) CN100379760C (OSRAM)
AR (2) AR010752A1 (OSRAM)
AT (1) ATE420893T1 (OSRAM)
AU (1) AU725731B2 (OSRAM)
BR (1) BRPI9713914B1 (OSRAM)
CA (1) CA2274149C (OSRAM)
CO (1) CO5080768A1 (OSRAM)
DE (1) DE69739219D1 (OSRAM)
ES (1) ES2321038T3 (OSRAM)
HR (1) HRP970683B1 (OSRAM)
MA (1) MA26454A1 (OSRAM)
PA (1) PA8442601A1 (OSRAM)
PE (1) PE27599A1 (OSRAM)
SV (1) SV1997000104A (OSRAM)
TN (1) TNSN97201A1 (OSRAM)
TR (2) TR200401638T2 (OSRAM)
TW (1) TW515804B (OSRAM)
UY (1) UY24805A1 (OSRAM)
WO (1) WO1998025965A2 (OSRAM)
ZA (1) ZA9711045B (OSRAM)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
PT885242E (pt) * 1995-06-07 2008-06-18 Glaxo Group Ltd Péptidos e compostos que se ligam a um receptor de trombopoietina
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
WO1999022732A1 (en) 1997-10-31 1999-05-14 Smithkline Beecham Corporation Novel metal complexes
CA2308317A1 (en) 1997-10-31 1999-05-14 Smithkline Beecham Corporation Novel metal complexes
JP2001521897A (ja) * 1997-10-31 2001-11-13 スミスクライン・ビーチャム・コーポレイション 新規な金属錯体
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
ATE348163T1 (de) * 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
WO2001021163A2 (en) * 1999-09-21 2001-03-29 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
US7332275B2 (en) 1999-10-13 2008-02-19 Sequenom, Inc. Methods for detecting methylated nucleotides
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2387805C (en) 1999-11-18 2012-08-28 Corvas International, Inc. Nucleic acids encoding endotheliases, endotheliases and uses thereof
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US7700341B2 (en) * 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
MXPA02010787A (es) * 2000-05-03 2003-07-14 Amgen Inc Peptidos modificados como agentes terapeuticos.
US20050158838A1 (en) * 2000-06-19 2005-07-21 Dyax Corp., A Delaware Corporation Novel enterokinase cleavage sequences
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
ES2258558T3 (es) * 2000-12-05 2006-09-01 Alexion Pharmaceuticals, Inc. Anticuerpos diseñados racionalmente.
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
WO2002072786A2 (en) 2001-03-13 2002-09-19 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
JP2004535166A (ja) 2001-03-22 2004-11-25 デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー セリンプロテアーゼｃｖｓｐ１４をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
KR20030096292A (ko) 2001-03-27 2003-12-24 덴드레온 샌 디에고 엘엘씨 트랜스막 세린 프로테아제 9를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
AU2002357004A1 (en) * 2001-11-20 2003-06-10 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
AU2003228809A1 (en) 2002-05-03 2003-11-17 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
DK1504098T4 (da) 2002-05-17 2011-05-23 Alligator Bioscience Ab Fremgangsmåde til molekyulær udvikling in vitro af proteinfunktion
CA2448513A1 (en) * 2002-06-29 2003-12-29 Aquanova German Solubilisate Technologies (Agt) Gmbh Isoflavone concentrates, as well as methods for their production
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
CA2495184A1 (en) 2002-08-14 2004-02-26 Nissan Chemical Industries, Ltd. Thrombopoietin receptor activators and process for their production
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US8227411B2 (en) * 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7166574B2 (en) 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7981862B2 (en) 2003-08-19 2011-07-19 Biosurface Engineering Technologies, Inc. Composition comprising BMP-2 amplifier/co-activator for enhancement of osteogenesis
KR20050093759A (ko) * 2002-09-18 2005-09-23 오르토-맥네일 파마슈티칼, 인코퍼레이티드 혈소판 및 조혈 줄기세포의 생산을 증가시키는 방법
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
EP1638587A4 (en) 2003-02-14 2007-04-18 Univ Missouri RECIPROCAL PROCEDURES AND COMPOSITIONS CONCERNING PROTEASOMAL INTERFERENCE
NZ543905A (en) 2003-05-12 2008-07-31 Affymax Inc Peptides that bind to the erythropoietin receptor
ATE478093T1 (de) * 2003-05-12 2010-09-15 Affymax Inc Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
NZ543934A (en) * 2003-05-12 2008-06-30 Affymax Inc Novel spacer moiety for poly (ethylene glycol)-modified peptide-based compounds
NZ543935A (en) * 2003-05-12 2008-06-30 Affymax Inc Peptides that bind to the erythropoietin receptor
CN103130739B (zh) * 2003-08-12 2015-09-16 盐野义制药株式会社 具有血小板生成素受体激动作用的化合物
EP1675606B1 (en) * 2003-08-28 2017-04-05 Janssen Pharmaceuticals, Inc. Peptides and compounds that bind to thrombopoietin receptors
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
ATE376556T1 (de) 2003-12-31 2007-11-15 Hoffmann La Roche Verfahren zur peptidsynthese unter verwendung einer reduzierten menge an entschützungsmittel
US7414028B1 (en) * 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
EP1725576B1 (en) 2004-02-20 2010-09-22 Biosurface Engineering Technologies, Inc. Positive modulator of bone morphogenic protein-2
JP2008505928A (ja) * 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド 治療用ペプチド
US20060210542A1 (en) * 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
DK1797127T3 (en) 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006060148A2 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
TWI351954B (en) 2004-12-08 2011-11-11 Nissan Chemical Ind Ltd Heterocyclic compounds and thrombopoietin receptor
JP4973192B2 (ja) 2004-12-14 2012-07-11 日産化学工業株式会社 アミド化合物及びトロンボポエチンレセプター活性化剤
CA2600749C (en) 2005-03-10 2014-04-15 Nascacell Ip Gmbh Dimeric or multimeric microproteins
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
WO2006136450A2 (en) * 2005-06-23 2006-12-28 Aplagen Gmbh Supravalent compounds
CA2609319C (en) 2005-07-15 2014-02-04 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
US7960425B2 (en) 2005-07-20 2011-06-14 Nissan Chemical Industries, Ltd. Pyrazole compounds and thrombopoietin receptor activators
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007052808A1 (ja) 2005-11-07 2007-05-10 Nissan Chemical Industries, Ltd. ヒドラジド化合物及びトロンボポエチンレセプター活性化剤
US7879318B2 (en) 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
EP1986677A2 (en) * 2006-01-25 2008-11-05 Amgen Inc. Thrombopoietic compounds
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
EP2005185B1 (en) * 2006-03-22 2010-10-20 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
WO2007133811A2 (en) * 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
EP2025671A4 (en) 2006-06-07 2011-04-06 Nissan Chemical Ind Ltd NITROGENIC HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
US7981425B2 (en) * 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
JP2010520855A (ja) * 2007-01-31 2010-06-17 アフィーマックス・インコーポレイテッド 修飾基をポリペプチドおよびその他の高分子に結合するための窒素ベースのリンカー
EP2738257A1 (en) 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2008157824A2 (en) * 2007-06-21 2008-12-24 Conjuchem Biotechnologies Inc. Thrombopoietin peptide conjugates
WO2009029682A1 (en) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
US8183342B2 (en) * 2007-11-06 2012-05-22 Case Western Reserve University Method of treating chemotherapy-induced thrombocytopenia
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
US9175078B2 (en) 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
EP2620448A1 (en) 2008-05-01 2013-07-31 Amgen Inc. Anti-hepcidin antibodies and methods of use
JP2012521360A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｋｖ１．３の選択的かつ強力なペプチド阻害剤
WO2011012306A2 (en) 2009-07-30 2011-02-03 Aplagen Gmbh Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis
US8889732B2 (en) 2009-10-23 2014-11-18 Nissan Chemical Industries, Ltd. Fused heterocyclic compounds and thrombopoietin receptor activators
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
EP2725034B1 (en) 2010-09-22 2019-04-03 Amgen Inc. Carrier immunoglobulins with no specificity for human tissues and uses thereof
WO2014159242A1 (en) 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
MX380553B (es) 2014-09-11 2025-03-12 Bristol Myers Squibb Co Inhibidores macrocíclicos de las interacciones proteína/proteína de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1.
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
WO2016079219A1 (en) 2014-11-19 2016-05-26 Koninklijke Philips N.V. Diagnostic method employing hnl
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
EA038019B1 (ru) 2016-05-19 2021-06-23 Бристол-Маерс Сквибб Компани Иммуномодуляторы для пэт-визуализации
WO2018085750A2 (en) 2016-11-07 2018-05-11 Bristol-Myers Squibb Company Immunomodulators
US11066445B2 (en) 2017-06-23 2021-07-20 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of PD-1
JP7481252B2 (ja) * 2017-07-26 2024-05-10 ヤンセン ファーマシューティカ エヌ．ベー． 標的放射線治療誘発性血管完全性を保護する方法
JP7257393B2 (ja) 2017-10-03 2023-04-13 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤
EP3914281A1 (en) 2019-01-25 2021-12-01 Janssen Pharmaceutica NV Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
CN113905754B (zh) 2019-01-25 2025-03-11 詹森药业有限公司 减轻起疱剂和腐蚀性气体毒性作用的方法
AU2020211412A1 (en) 2019-01-25 2021-08-12 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
JP2023510737A (ja) 2020-01-06 2023-03-15 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤
KR20220161407A (ko) 2020-03-30 2022-12-06 브리스톨-마이어스 스큅 컴퍼니 면역조정제
EP4408984A1 (en) 2021-10-01 2024-08-07 Janssen Pharmaceutica NV Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2046920B1 (OSRAM) 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4612132A (en) 1984-07-20 1986-09-16 Chevron Research Company Modified succinimides
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5198424A (en) * 1989-03-08 1993-03-30 Board Of Regents Of The University Of Oklahoma Functionally active selectin-derived peptides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) * 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
US5571508A (en) * 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) * 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
JPH07507806A (ja) * 1992-06-11 1995-08-31 アルカーメス　コントロールド　セラピューティクス，インコーポレイテッド エリスロポエチン薬物送達システム
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
AU685506B2 (en) 1993-08-25 1998-01-22 Systemix, Inc. Method for producing a highly enriched population of hematopoietic stem cells
AU8124694A (en) * 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SG47030A1 (en) * 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
WO1995021626A1 (en) * 1994-02-14 1995-08-17 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
EP0668352A1 (en) * 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein having TPO activity
CZ221496A3 (en) * 1994-02-14 1997-07-16 Zymogenetics Inc Haematopoetic protein, materials and processes for preparing thereof
TW496870B (en) * 1994-03-31 2002-08-01 Amgen Inc Compositions methods for stimulating megakaryocyte growth and differentiation
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
AU4163196A (en) * 1994-11-30 1996-06-19 Zymogenetics Inc. Low molecular weight thrombopoietin
ES2276401T3 (es) * 1995-04-26 2007-06-16 Kyowa Hakko Kogyo Co., Ltd. Proteinas de fusion g-csf tpo.
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
PT885242E (pt) * 1995-06-07 2008-06-18 Glaxo Group Ltd Péptidos e compostos que se ligam a um receptor de trombopoietina
KR102127408B1 (ko) 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체

Also Published As

Publication number Publication date
EP0948539B1 (en) 2009-01-14
EP0948539A2 (en) 1999-10-13
HRP970683B1 (en) 2002-10-31
US6121238A (en) 2000-09-19
KR100668546B1 (ko) 2007-01-16
DE69739219D1 (de) 2009-03-05
MA26454A1 (fr) 2004-12-20
ATE420893T1 (de) 2009-01-15
KR100679576B1 (ko) 2007-02-07
CO5080768A1 (es) 2001-09-25
CA2274149C (en) 2008-07-15
ES2321038T3 (es) 2009-06-01
HRP970683A2 (en) 1998-10-31
WO1998025965A3 (en) 1998-08-13
CA2274149A1 (en) 1998-06-18
UY24805A1 (es) 2000-12-29
JP4128225B2 (ja) 2008-07-30
TW515804B (en) 2003-01-01
WO1998025965A2 (en) 1998-06-18
AU5854798A (en) 1998-07-03
TR199901971T2 (xx) 1999-12-21
JP2001505898A (ja) 2001-05-08
ZA9711045B (en) 1999-06-09
KR20050042505A (ko) 2005-05-09
US5869451A (en) 1999-02-09
TR200401638T2 (tr) 2004-11-22
KR20060025611A (ko) 2006-03-21
PE27599A1 (es) 1999-03-29
TNSN97201A1 (fr) 2005-03-15
CN1245504A (zh) 2000-02-23
AR010752A1 (es) 2000-07-12
PA8442601A1 (es) 2000-05-24
EP2336165A1 (en) 2011-06-22
AR062931A2 (es) 2008-12-17
BR9713914A (pt) 2000-02-29
EP2028191A1 (en) 2009-02-25
CN100379760C (zh) 2008-04-09
BRPI9713914B1 (pt) 2017-06-20
AU725731B2 (en) 2000-10-19
KR100625708B1 (ko) 2006-09-20
KR20000069408A (ko) 2000-11-25
SV1997000104A (es) 1998-09-18

Similar Documents

Publication Publication Date Title
AR026661A2 (OSRAM)
BRPI9713914B8 (OSRAM)
IN191431B (OSRAM)
BR7600721U (OSRAM)
BR7601346U (OSRAM)
BR9603859A (OSRAM)
CN3045853S (OSRAM)
CN3039060S (OSRAM)
CN3039213S (OSRAM)
CN3040024S (OSRAM)
CN3040367S (OSRAM)
CN3040543S (OSRAM)
CN3040550S (OSRAM)
CN3040805S (OSRAM)
CN3041115S (OSRAM)
CN3041207S (OSRAM)
CN3041374S (OSRAM)
CN3041383S (OSRAM)
CN3042193S (OSRAM)
CN3042289S (OSRAM)
CN3042424S (OSRAM)
CN3042589S (OSRAM)
CN3043305S (OSRAM)
CN3043413S (OSRAM)
CN3043414S (OSRAM)

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO, DE ACORDO COM ARTIGO 8O DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/12/1997 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 09/12/2017